Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P522 | DOI: 10.1530/endoabs.35.P522

1Department of Endocrinology and Metabolism, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey; 2Department of General Surgery, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.


Background: Adrenal carcinoma is rare endocrine cancer. Survival time is short and primary treatment is surgery.

Methods: Four patients with histopathologically diagnosed as adrenal carcinoma between 2007 and 2013 were evaluated retrospectively.

Results: Two of the patients were female and others were male. Their ages were 39, 50, 55 and 61 respectively. All the patients were admitted to the hospital with abdominal pain. Tumor diameters of the cases were 20, 18, 5 and 11 cm respectively. Tumor was on left side in three patients and on the right side in one patient. Three patients had active hormone secreting tumors that was cortisol. One patient had hormone-inactive tumor. Two patients were stage 4, one patient was stage 2 and one patient was stage 1 according to TNM classification. Two patients were treated with mitotane. Three of the patients died 5, 14 and 15 months after the operation respectively. One patient (39 years old, stage 2) is alive for 4.5 years after the operation.

Conclusion: Adrenal carcinomas have bad prognosis. The patients have been diagnosed at late stages. The most important survival criteria is complete surgical resection. The age of the patient at diagnosis might be an another survival factor. Mitotane treatment might be used in selected patients.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts